

Naloxone Distribution Project

About the NDP

DHCS created the Naloxone Distribution Project (NDP) to combat opioid overdose-related deaths throughout California. The NDP aims to address the opioid crisis by reducing opioid overdose deaths through the provision of free naloxone. For more information on the NDP, please visit the CaliforniaMAT (<https://www.californiamat.org/matproject/naloxone-distribution-project/>) website.

How to Apply Via the New Online NDP Portal

Applications to the NDP must be submitted via the NDP online application form (https://aurerhealthgroup.qualtrics.com/jfe/form/SV_3aqWz9n74FH7tVs). Please review the below table and FAQs for any additional required materials for your organization's application.

To apply for naloxone through the NDP:

1. Obtain a standing order.
2. Gather the required supplemental materials.
3. Complete the NDP online application form.
4. Submit the application and supplemental materials via the NDP online application form.

Required Materials

Obtain a Standing Order

As noted in the table below, all NDP applicants must submit a prescription or standing order for naloxone with their application. If your organization does not have a standing order, one can be obtained from the California Department of Public Health's Website (<https://www.cdph.ca.gov/Programs/CCDPHP/sapb/Pages/Naloxone-Standing-Order.aspx>). When

you submit your request for a Standing Order to the Department of Public Health (when you click the submit button) it generates a document that you have to save as a PDF or Word document on your desktop and then submit a copy to DHCS.

In addition to the standing order described above, eligible entities, noted in the chart below by Organization Type, must also submit the following materials for application approval:

Organization Type	Required Materials
<ul style="list-style-type: none">• First responders, fire, EMS• Law enforcement, courts, & criminal justice partners• Community organizations (including libraries, veteran organizations, and religious organizations)• Harm reductions organizations• Schools, universities• County public health or behavioral health agencies• Local city agencies• Tribal entities	<ul style="list-style-type: none">• A copy of a naloxone standing order or physician's prescription.• A copy of a valid and active business license, FEIN number or tax-exempt letter.• For orders over 48 units, policies and procedures for naloxone distribution including:<ul style="list-style-type: none">◦ Storage of naloxone received through the program;◦ Inventory and tracking of naloxone received through the program;◦ Distribution plan for naloxone received through the program• Number of overdose reversals reported with naloxone received through NDP (for subsequent applications)

Organizations that serve unhoused populations	<ul style="list-style-type: none"> • A copy of a naloxone standing order or physician's prescription. • A copy of a valid and active business license, FEIN number or tax-exempt letter. • For orders over 48 units, policies and procedures for naloxone distribution including: <ul style="list-style-type: none"> ◦ Storage of naloxone received through the program; ◦ Inventory and tracking of naloxone received through the program; ◦ Distribution plan for naloxone received through the program • <u>Completed certification of services for unhoused individuals</u> (/Documents/CSD/OSF-Organization-Eligibility.pdf). • Number of overdose reversals reported with naloxone received through NDP (for subsequent applications)
Substance Use Recovery Facilities (inpatient, outpatient, residential, sober living homes)	<ul style="list-style-type: none"> • A copy of a naloxone standing order or physician's prescription. • A copy of a valid and active business license, FEIN number or tax-exempt letter. • Copy of the program's DHCS license (if applicable) • Policies and procedures for naloxone distribution, including: <ul style="list-style-type: none"> ◦ Separate storage of naloxone received through the program from other medications that may be billed to patient insurance; ◦ Inventory and tracking of naloxone received through the program; ◦ Distribution plan for naloxone received through the program • Number of overdose reversals reported with naloxone received through NDP (for subsequent applications)

<ul style="list-style-type: none"> • Hospitals and Emergency Departments • Federally Qualified Health Centers (FQHC) • Community clinics 	<ul style="list-style-type: none"> • A copy of a naloxone standing order or physician's prescription. • A copy of a valid and active business license, FEIN number or tax-exempt letter. • Policies and procedures for naloxone distribution <ul style="list-style-type: none"> ◦ Separate storage of naloxone received through the program from other medications that may be billed to patient insurance; ◦ Inventory and tracking of naloxone received through the program; ◦ Distribution plan for naloxone received through the program • Number of overdose reversals reported with naloxone received through NDP (for subsequent applications)
---	---

More questions? Refer to the [NDP Information & FAQs \(/Documents/CSD/NDP-FAQs-04-2023.pdf\)](/Documents/CSD/NDP-FAQs-04-2023.pdf).

NDP Participants are required to maintain detailed distribution logs and reversal reporting documentation – DHCS may require review of this additional information prior to approving subsequent applications.

NDP Resources

[NDP Overview \(/individuals/Documents/NDP_Overview.pdf\)](/individuals/Documents/NDP_Overview.pdf).

[\(/Documents/CSD/Naloxone-Distribution-Project-FAQ-12-13-22.pdf\)](/Documents/CSD/Naloxone-Distribution-Project-FAQ-12-13-22.pdf) NDP Information & FAQs

[\(/Documents/CSD/NDP-FAQs-04-2023.pdf\)](/Documents/CSD/NDP-FAQs-04-2023.pdf).

Contact Us

Questions? Contact NDP Team by email: Naloxone@dhcs.ca.gov (<mailto:Naloxone@dhcs.ca.gov>).

Alerts and Urgent Updates

The U.S. Food and Drug Administration (https://gcc02.safelinks.protection.outlook.com/?url=https://urldefense.com/v3/_https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray_%3b%21%21EuW5fDSpzeg%21JZvMayKSE6yl-wnsTgzaTM2Ug6SJku_0fHcjMYSTPZKaDINTh60Jkv1YMajFAh07PQWEdjjovPCSokUPDRbFaNwLb89oE)

[n6madOg\\$&data=05%7c01%7cYee.Vue%40dhcs.ca.gov%7c7108e99d0d67493d2a7d08db3619915a%7c265c2dcd2a6e43aab2e826421a8c8526%7c0%7c0%7c638163255681611305%7cUnknown%7cTWFpbGZsb3d8eyJWljoimc4wLjAwMDAiLCJQljoiv2luMzliLCJBTiI6lk1haWwiLCJXVCI6Mn0%3D%7c3000%7c%7c%7c&sdata=XroFe2BICbFBgy7dbCSyfw%2BcjtywRon4e8VdHdY0/SA%3D&reserved=0](https://www.dhcs.ca.gov/n6madOg$&data=05%7c01%7cYee.Vue%40dhcs.ca.gov%7c7108e99d0d67493d2a7d08db3619915a%7c265c2dcd2a6e43aab2e826421a8c8526%7c0%7c0%7c638163255681611305%7cUnknown%7cTWFpbGZsb3d8eyJWljoimc4wLjAwMDAiLCJQljoiv2luMzliLCJBTiI6lk1haWwiLCJXVCI6Mn0%3D%7c3000%7c%7c%7c&sdata=XroFe2BICbFBgy7dbCSyfw%2BcjtywRon4e8VdHdY0/SA%3D&reserved=0)),

(FDA) approved Narcan, a 4 milligram (mg) naloxone hydrochloride nasal spray, for over-the-counter (OTC), nonprescription use on March 29, 2023. This action paves the way for the live-saving medication to reverse an opioid overdose to be sold directly to consumers. The timeline for availability and price of the OTC product is determined by the manufacturer. The FDA will work with all stakeholders to help facilitate the continued availability of naloxone nasal spray products during Narcan's transition from prescription to OTC status, which may take months. The FDA hosted a stakeholder call to share information on expanding access to naloxone on March 30, 2023. [Click here \(https://gcc02.safelinks.protection.outlook.com/?url=https://urldefense.com/v3/_https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDQsInVyaSI6ImJwMjpbGljaylslmJ1bGxldGluX2lkIjoimjAyMzA0MDUuNzQ2NTE4NTEiLCJ1cmwiOiJodHRwczovL3lvdXR1LmJlL29yb29yZm90bV9tZWVpdW09ZW1haWwmdXRtX3NvdXJjZT1nb3ZkZWxpdmVyeSJ9.VS2hgZu2Bpx4pjTE1F5zllb5pA_O8rxpUFtdCry0tGM/s/2986962027/br/157409160071-l_%3b%21%21EuW5fDSpzeg%21c9BuuP4qDVjm-zLjuBk8ar-DOK1VQcL7XnK8DS0sAEpni2t3HzSY8p0wVMfS51-vgfy759s8hFrUOYcK1Jm3JBXKxCS6OFKPOftWA\\$&data=05%7c01%7cYee.Vue%40dhcs.ca.gov%7c7108e99d0d67493d2a7d08db3619915a%7c265c2dcd2a6e43aab2e826421a8c8526%7c0%7c0%7c638163255681611305%7cUnknown%7cTWFpbGZsb3d8eyJWljoimc4wLjAwMDAiLCJQljoiv2luMzliLCJBTiI6lk1haWwiLCJXVCI6Mn0%3D%7c3000%7c%7c%7c&sdata=RbbNg3QhYb7WzoWvWMjgmgRZ3xdajSgd252H4nqICvk%3D&reserved=0\)](https://gcc02.safelinks.protection.outlook.com/?url=https://urldefense.com/v3/_https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDQsInVyaSI6ImJwMjpbGljaylslmJ1bGxldGluX2lkIjoimjAyMzA0MDUuNzQ2NTE4NTEiLCJ1cmwiOiJodHRwczovL3lvdXR1LmJlL29yb29yZm90bV9tZWVpdW09ZW1haWwmdXRtX3NvdXJjZT1nb3ZkZWxpdmVyeSJ9.VS2hgZu2Bpx4pjTE1F5zllb5pA_O8rxpUFtdCry0tGM/s/2986962027/br/157409160071-l_%3b%21%21EuW5fDSpzeg%21c9BuuP4qDVjm-zLjuBk8ar-DOK1VQcL7XnK8DS0sAEpni2t3HzSY8p0wVMfS51-vgfy759s8hFrUOYcK1Jm3JBXKxCS6OFKPOftWA$&data=05%7c01%7cYee.Vue%40dhcs.ca.gov%7c7108e99d0d67493d2a7d08db3619915a%7c265c2dcd2a6e43aab2e826421a8c8526%7c0%7c0%7c638163255681611305%7cUnknown%7cTWFpbGZsb3d8eyJWljoimc4wLjAwMDAiLCJQljoiv2luMzliLCJBTiI6lk1haWwiLCJXVCI6Mn0%3D%7c3000%7c%7c%7c&sdata=RbbNg3QhYb7WzoWvWMjgmgRZ3xdajSgd252H4nqICvk%3D&reserved=0) to access the recording of the Expanding Access to Naloxone stakeholder call.

[https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDQsInVyaSI6ImJwMjpbGljaylslmJ1bGxldGluX2lkIjoimjAyMzA0MDUuNzQ2NTE4NTEiLCJ1cmwiOiJodHRwczovL3lvdXR1LmJlL29yb29yZm90bV9tZWVpdW09ZW1haWwmdXRtX3NvdXJjZT1nb3ZkZWxpdmVyeSJ9.VS2hgZu2Bpx4pjTE1F5zllb5pA_O8rxpUFtdCry0tGM/s/2986962027/br/157409160071-l_%3b%21%21EuW5fDSpzeg%21c9BuuP4qDVjm-zLjuBk8ar-DOK1VQcL7XnK8DS0sAEpni2t3HzSY8p0wVMfS51-](https://urldefense.com/v3/_https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDQsInVyaSI6ImJwMjpbGljaylslmJ1bGxldGluX2lkIjoimjAyMzA0MDUuNzQ2NTE4NTEiLCJ1cmwiOiJodHRwczovL3lvdXR1LmJlL29yb29yZm90bV9tZWVpdW09ZW1haWwmdXRtX3NvdXJjZT1nb3ZkZWxpdmVyeSJ9.VS2hgZu2Bpx4pjTE1F5zllb5pA_O8rxpUFtdCry0tGM/s/2986962027/br/157409160071-l_%3b%21%21EuW5fDSpzeg%21c9BuuP4qDVjm-zLjuBk8ar-DOK1VQcL7XnK8DS0sAEpni2t3HzSY8p0wVMfS51-vgfy759s8hFrUOYcK1Jm3JBXKxCS6OFKPOftWA$&data=05%7c01%7cYee.Vue%40dhcs.ca.gov%7c7108e99d0d67493d2a7d08db3619915a%7c265c2dcd2a6e43aab2e826421a8c8526%7c0%7c0%7c638163255681611305%7cUnknown%7cTWFpbGZsb3d8eyJWljoimc4wLjAwMDAiLCJQljoiv2luMzliLCJBTiI6lk1haWwiLCJXVCI6Mn0%3D%7c3000%7c%7c%7c&sdata=RbbNg3QhYb7WzoWvWMjgmgRZ3xdajSgd252H4nqICvk%3D&reserved=0)

[vgfy759s8hFrUOYcK1Jm3JBXKxCS6OFKPOftWA\\$&data=05%7c01%7cYee.Vue%40dhcs.ca.gov%7c7108e99d0d67493d2a7d08db3619915a%7c265c2dcd2a6e43aab2e826421a8c8526%7c0%7c0%7c638163255681611305%7cUnknown%7cTWFpbGZsb3d8eyJWljoimc4wLjAwMDAiLCJQljoiv2luMzliLCJBTiI6lk1haWwiLCJXVCI6Mn0%3D%7c3000%7c%7c%7c&sdata=RbbNg3QhYb7WzoWvWMjgmgRZ3xdajSgd252H4nqICvk%3D&reserved=0](https://urldefense.com/v3/_https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDQsInVyaSI6ImJwMjpbGljaylslmJ1bGxldGluX2lkIjoimjAyMzA0MDUuNzQ2NTE4NTEiLCJ1cmwiOiJodHRwczovL3lvdXR1LmJlL29yb29yZm90bV9tZWVpdW09ZW1haWwmdXRtX3NvdXJjZT1nb3ZkZWxpdmVyeSJ9.VS2hgZu2Bpx4pjTE1F5zllb5pA_O8rxpUFtdCry0tGM/s/2986962027/br/157409160071-l_%3b%21%21EuW5fDSpzeg%21c9BuuP4qDVjm-zLjuBk8ar-DOK1VQcL7XnK8DS0sAEpni2t3HzSY8p0wVMfS51-vgfy759s8hFrUOYcK1Jm3JBXKxCS6OFKPOftWA$&data=05%7c01%7cYee.Vue%40dhcs.ca.gov%7c7108e99d0d67493d2a7d08db3619915a%7c265c2dcd2a6e43aab2e826421a8c8526%7c0%7c0%7c638163255681611305%7cUnknown%7cTWFpbGZsb3d8eyJWljoimc4wLjAwMDAiLCJQljoiv2luMzliLCJBTiI6lk1haWwiLCJXVCI6Mn0%3D%7c3000%7c%7c%7c&sdata=RbbNg3QhYb7WzoWvWMjgmgRZ3xdajSgd252H4nqICvk%3D&reserved=0)),

Other formulations and dosages of naloxone will remain available by prescription only. There are no changes to California's Naloxone Distribution Project (NDP) as a result of the FDA decision at this time. DHCS is monitoring the progress of OTC Narcan closely and will provide more updates as they become available.

Xylazine Alert

Earlier today, SAMHSA released a [The Dear Colleague Letter \(https://www.samhsa.gov/sites/default/files/colleague-letter-xylazine.pdf?utm_source=SAMHSA&utm_campaign=cd479430f6-EMAIL_CAMPAIGN_2023_03_28_01_19&utm_medium=email&utm_term=0_-cd479430f6-%5bLIST_EMAIL_ID%5d\)](https://www.samhsa.gov/sites/default/files/colleague-letter-xylazine.pdf?utm_source=SAMHSA&utm_campaign=cd479430f6-EMAIL_CAMPAIGN_2023_03_28_01_19&utm_medium=email&utm_term=0_-cd479430f6-%5bLIST_EMAIL_ID%5d) to providers and grantees about the risks of xylazine. According to the press release, "SAMHSA's goal with this alert is to provide information about the consequences of xylazine exposure, what practitioners can do to mitigate harm, and how SAMHSA is responding to this

emerging public health challenge. SAMHSA thanks grantees and providers for their vital role in carrying out this life-saving work.”

Please visit the [California Department of Public Health](https://www.cdph.ca.gov/Programs/CCDPHP/sapb/Pages/Xylazine.aspx) (<https://www.cdph.ca.gov/Programs/CCDPHP/sapb/Pages/Xylazine.aspx>) webpage on Xylazine. For more information on the emerging threat of Xylazine, click [here](https://www.cossapresources.org/Content/Documents/Articles/RTI_Emerging_Threat_of_Xylazine_April_2023.pdf). (https://www.cossapresources.org/Content/Documents/Articles/RTI_Emerging_Threat_of_Xylazine_April_2023.pdf).

Last modified date: 7/7/2023 8:44 AM

Non-Discrimination Policy and Language Access (/Pages/Language_Access.aspx).

Access Health Care Language Assistance Services (SB 223).
(/Pages/Health_Care_Language_Assistance_Services.aspx).

[العربية \(/Pages/Language_Access.aspx#arabic\)](/Pages/Language_Access.aspx#arabic). | [Հայերեն \(/Pages/Language_Access.aspx#armenian\)](/Pages/Language_Access.aspx#armenian). | [ខ្មែរ \(/Pages/Language_Access.aspx#cambodian\)](/Pages/Language_Access.aspx#cambodian). | [繁體中文 \(/Pages/Language_Access.aspx#chinese\)](/Pages/Language_Access.aspx#chinese). | [فارسی \(/Pages/Language_Access.aspx#farsi\)](/Pages/Language_Access.aspx#farsi). | [हिंदी \(/Pages/Language_Access.aspx#hindi\)](/Pages/Language_Access.aspx#hindi). | [Hmoob \(/Pages/Language_Access.aspx#hmong\)](/Pages/Language_Access.aspx#hmong). | [日本語 \(/Pages/Language_Access.aspx#japanese\)](/Pages/Language_Access.aspx#japanese). | [한국어 \(/Pages/Language_Access.aspx#korean\)](/Pages/Language_Access.aspx#korean). | [ລາວ \(/Pages/Language_Access.aspx#laotian\)](/Pages/Language_Access.aspx#laotian). | [Mienh waac \(/Pages/Language_Access.aspx#mienhwaac\)](/Pages/Language_Access.aspx#mienhwaac). | [ਪੰਜਾਬੀ \(/Pages/Language_Access.aspx#punjabi\)](/Pages/Language_Access.aspx#punjabi). | [Русский \(/Pages/Language_Access.aspx#russian\)](/Pages/Language_Access.aspx#russian). | [Español \(/Pages/Language_Access.aspx#spanish\)](/Pages/Language_Access.aspx#spanish). | [Tagalog \(/Pages/Language_Access.aspx#tagalog\)](/Pages/Language_Access.aspx#tagalog). | [ภาษาไทย \(/Pages/Language_Access.aspx#thai\)](/Pages/Language_Access.aspx#thai). | [Українська \(/Pages/Language_Access.aspx#ukrainian\)](/Pages/Language_Access.aspx#ukrainian). | [Tiếng Việt \(/Pages/Language_Access.aspx#vietnamese\)](/Pages/Language_Access.aspx#vietnamese).

[About Us \(/Pages/AboutUs.aspx\)](/Pages/AboutUs.aspx). | [Careers \(/services/admin/jobs/Pages/default.aspx\)](/services/admin/jobs/Pages/default.aspx). | [Conditions of Use \(/pages/use.aspx\)](/pages/use.aspx). | [Privacy Policy \(/pages/privacy.aspx\)](/pages/privacy.aspx). | [Contact Us \(/Pages/contact_us.aspx\)](/Pages/contact_us.aspx). | [Accessibility Certification \(/Documents/Web-Accessibility-Cert.pdf\)](/Documents/Web-Accessibility-Cert.pdf).

Copyright © 2023 State of California

